AxoGen, Inc (NASDAQ:AXGN) VP Michael Patrick Donovan sold 20,000 shares of AxoGen stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $20.00, for a total transaction of $400,000.00. Following the sale, the vice president now directly owns 18,974 shares of the company’s stock, valued at approximately $379,480. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Shares of NASDAQ AXGN opened at $20.25 on Friday. AxoGen, Inc has a twelve month low of $14.13 and a twelve month high of $56.85. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.83 and a quick ratio of 8.03.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings results on Wednesday, May 8th. The medical equipment provider reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The firm had revenue of $23.30 million for the quarter, compared to the consensus estimate of $22.33 million. AxoGen had a negative return on equity of 15.58% and a negative net margin of 29.19%. The company’s revenue for the quarter was up 34.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.11) earnings per share. As a group, equities analysts expect that AxoGen, Inc will post -0.74 earnings per share for the current fiscal year.

AXGN has been the subject of a number of analyst reports. BidaskClub lowered shares of AxoGen from a “hold” rating to a “sell” rating in a report on Wednesday. ValuEngine raised shares of AxoGen from a “hold” rating to a “buy” rating in a report on Wednesday, May 1st. BTIG Research raised shares of AxoGen from a “neutral” rating to a “buy” rating and set a $28.00 target price for the company in a report on Monday, March 25th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $30.00 target price (up previously from $26.00) on shares of AxoGen in a report on Thursday, May 9th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $38.00.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Raymond James & Associates boosted its position in shares of AxoGen by 4.1% during the first quarter. Raymond James & Associates now owns 15,989 shares of the medical equipment provider’s stock worth $337,000 after purchasing an additional 634 shares in the last quarter. Legal & General Group Plc boosted its position in shares of AxoGen by 5.8% during the fourth quarter. Legal & General Group Plc now owns 12,826 shares of the medical equipment provider’s stock worth $262,000 after purchasing an additional 702 shares in the last quarter. Quantamental Technologies LLC boosted its position in shares of AxoGen by 108.3% during the first quarter. Quantamental Technologies LLC now owns 1,431 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 744 shares in the last quarter. Advisor Group Inc. boosted its position in shares of AxoGen by 130.3% during the first quarter. Advisor Group Inc. now owns 1,368 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 774 shares in the last quarter. Finally, Cutler Group LP boosted its position in shares of AxoGen by 120.0% during the first quarter. Cutler Group LP now owns 2,200 shares of the medical equipment provider’s stock worth $46,000 after purchasing an additional 1,200 shares in the last quarter. 87.40% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Michael Patrick Donovan Sells 20,000 Shares of AxoGen, Inc (NASDAQ:AXGN) Stock” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.dailypolitical.com/2019/06/16/michael-patrick-donovan-sells-20000-shares-of-axogen-inc-nasdaqaxgn-stock.html.

About AxoGen

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Featured Story: Diluted Earnings Per Share

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.